Cellectis S.A. - American Depositary Shares – Cashflow (NASDAQ:CLLS)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit 80.26 M104.56 M87.44 M24.75 M22.99 M39.4 M — Mittelzufluss aus Investitionstätigkeit 54.34 M7.28 M2.76 M15.51 M102.81 M29.48 M — Zahlungsströme aus der Finanzierungstätigkeit 27.32 M47.52 M1.15 M82.86 M89.11 M16.76 M — Freier Cashflow 80.26 M104.56 M87.44 M24.75 M22.99 M39.4 M —

Cellectis S.A. - American Depositary Shares

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Allogene Therapeutics (NASDAQ:ALLO), Cellectis (NASDAQ:CLLS)

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Argo Blockchain (NASDAQ:ARBK), Ascent Solar Technologies (NASDAQ:ASTI)

CLLS

Financials